tiprankstipranks
Trending News
More News >
Ufp Technologies (UFPT)
:UFPT

Ufp Technologies (UFPT) AI Stock Analysis

Compare
160 Followers

Top Page

UFPT

Ufp Technologies

(NASDAQ:UFPT)

Select Model
Select Model
Select Model
Outperform 75 (OpenAI - 4o)
Rating:75Outperform
Price Target:
$243.00
▲(22.08% Upside)
UFP Technologies' strong financial performance and strategic focus on high-margin opportunities in the medical device market are significant strengths. However, mixed technical indicators and operational challenges, particularly labor inefficiencies, present risks. The company's moderate valuation and future growth prospects in MedTech and robotic surgery are promising, but current challenges need to be addressed to fully realize potential.
Positive Factors
Revenue Growth
Consistent revenue growth, particularly in the MedTech segment, indicates strong market demand and effective business strategies, supporting long-term expansion.
Strategic Focus
Focusing on high-margin opportunities in the medical device market strengthens customer relationships and expands market presence, enhancing competitive advantage.
Cash Flow Generation
Strong cash flow generation supports ongoing operations and growth initiatives, providing financial flexibility and stability for future investments.
Negative Factors
Labor Inefficiencies
Labor inefficiencies at the AJR facility impact profitability and operational efficiency, posing a risk to sustained financial performance.
Leadership Transition
Leadership transitions can introduce uncertainty and potential strategic shifts, affecting company direction and stakeholder confidence.
Order Fulfillment Challenges
Challenges in fulfilling orders due to labor issues can hinder revenue growth and customer satisfaction, impacting long-term business relationships.

Ufp Technologies (UFPT) vs. SPDR S&P 500 ETF (SPY)

Ufp Technologies Business Overview & Revenue Model

Company DescriptionUFP Technologies, Inc. (UFPT) is a leading manufacturer of custom-engineered protective packaging, molded and fabricated products, and specialty foam solutions. The company operates primarily in the industrial, medical, and consumer markets, providing innovative solutions that cater to the specific needs of its clients. UFP Technologies leverages advanced materials and manufacturing processes to deliver high-quality products designed to protect and enhance the value of its customers' goods.
How the Company Makes MoneyUFP Technologies generates revenue through the sale of its custom-engineered products, which are primarily focused on protective packaging, molded products, and specialty foam solutions. The company has multiple key revenue streams, including direct sales to customers in diverse sectors such as healthcare, automotive, and electronics. Additionally, UFP Technologies benefits from long-term contracts with major clients that ensure a steady flow of income. The company also invests in research and development to innovate and expand its product offerings, which helps maintain competitive advantage and drive sales growth. Strategic partnerships with suppliers and collaborations with clients for customized solutions further enhance its revenue potential, allowing UFP Technologies to capture a larger market share.

Ufp Technologies Earnings Call Summary

Earnings Call Date:Nov 03, 2025
(Q3-2025)
|
Next Earnings Date:Mar 10, 2026
Earnings Call Sentiment Neutral
The earnings call reflected a mix of positive growth in key business areas like MedTech and robotic surgery, along with successful integration of recent acquisitions. However, significant challenges due to labor inefficiencies at the AJR facility and declines in certain segments were notable. The company is optimistic about future growth, particularly with ongoing discussions to expand major contracts, but current inefficiencies remain a concern.
Q3-2025 Updates
Positive Updates
Overall Sales Growth
Overall sales grew 6.5% to $154.6 million, driven by MedTech business growth of 7.3%.
MedTech Segment Success
Interventional and Surgical, Orthopedics, and Wound Care each grew greater than 30%.
Robotic Surgery Program Launch
Two significant new programs are expected to contribute greater than $10 million in 2026, with further growth anticipated.
Positive Acquisition Performance
Recent acquisitions, UNIPEC and TPI, performed well ahead of expectations and were immediately accretive to earnings.
Reduction in Interest Expense
Interest expense was down significantly due to deleveraging of the balance sheet.
Contract Expansion Discussions
Discussions are underway to extend and expand a contract with the largest customer, including planning for significantly increased volumes.
Negative Updates
Labor Inefficiency at AJR Facility
High costs due to labor inefficiency led to a $3 million reduction in gross profit and operating income, and a $0.28 reduction in diluted EPS.
Decline in Patient Services and Support
A 23% decline in the AJR, Stryker business segment impacted overall performance.
Advanced Components Business Decline
The non-medical business segment declined 2.7% as focus shifted to MedTech.
Unfulfilled Orders Impact
Due to labor issues, more than $8 million in incremental orders were unable to be fulfilled, affecting organic growth.
Company Guidance
During UFP Technologies' third quarter 2025 earnings call, the company reported a 6.5% increase in overall sales to $154.6 million, despite facing significant labor inefficiencies at their AJR Illinois facility, which resulted in a $3 million reduction in gross profit and operating income, as well as a $0.28 decrease in diluted EPS. The MedTech segment saw impressive growth of 7.3%, driven by over 30% increases in Interventional and Surgical, Orthopedics, and Wound Care, although this was partially offset by a 23% decline in Patient Services and Support. The company's advanced components segment experienced a 2.7% decline, as resources were focused on MedTech. The labor issues at AJR led to more than 50% turnover in the workforce, causing a delay in fulfilling over $8 million in orders, which contributed to a backlog of $16 million heading into the fourth quarter. Despite these challenges, UFP remains optimistic, with expectations to ramp up capacity and work down the backlog, while also anticipating significant future growth in their robotic surgery programs, which are projected to generate over $10 million in revenue by 2026. The company is also in discussions to extend and expand their $500 million contract with their largest customer, with plans for substantial investments to increase capacity at their La Romana facilities. UFP's recent acquisitions, UNIPEC and TPI, have exceeded expectations and are contributing positively to earnings.

Ufp Technologies Financial Statement Overview

Summary
UFP Technologies shows strong financial performance with consistent revenue growth, solid profitability, and efficient cash flow management. The balance sheet is stable with moderate leverage, supporting ongoing operations and growth initiatives.
Income Statement
85
Very Positive
Ufp Technologies has demonstrated strong revenue growth with a TTM revenue growth rate of 1.60%, indicating robust expansion. The company maintains healthy profitability with a gross profit margin of 28.76% and a net profit margin of 11.40% for the TTM. EBIT and EBITDA margins are also solid at 16.06% and 19.13%, respectively, reflecting efficient operations. Overall, the income statement shows a positive trajectory with consistent growth and profitability.
Balance Sheet
78
Positive
The balance sheet is stable with a debt-to-equity ratio of 0.42, indicating moderate leverage. The return on equity is strong at 18.93%, showcasing effective use of equity to generate profits. The equity ratio stands at 61.87%, reflecting a solid capital structure with a significant portion of assets financed by equity. While the company has increased its debt over time, it remains at manageable levels.
Cash Flow
82
Very Positive
Cash flow metrics are robust, with a free cash flow growth rate of 20.53% in the TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 1.20, suggesting efficient conversion of income into cash. Additionally, the free cash flow to net income ratio of 0.87 highlights the company's ability to generate cash relative to its net income. Overall, cash flow performance is strong, supporting the company's growth and operational needs.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue597.95M504.42M400.07M353.79M206.32M179.37M
Gross Profit170.50M146.69M112.22M90.26M51.11M44.68M
EBITDA112.05M95.80M68.95M67.37M29.65M24.63M
Net Income67.12M58.98M44.92M41.79M15.89M13.37M
Balance Sheet
Total Assets652.82M629.00M404.14M378.19M334.13M203.20M
Cash, Cash Equivalents and Short-Term Investments18.23M13.45M5.26M4.45M11.12M24.23M
Total Debt165.51M206.03M46.04M68.37M84.36M2.21M
Total Liabilities248.91M286.24M118.05M140.65M139.69M26.31M
Stockholders Equity403.91M342.76M286.09M237.54M194.45M176.89M
Cash Flow
Free Cash Flow54.88M56.94M30.84M3.96M8.90M20.67M
Operating Cash Flow63.56M66.59M41.33M17.74M14.29M25.04M
Investing Cash Flow-12.35M-210.16M-10.49M1.29M-101.46M-4.26M
Financing Cash Flow-52.50M152.39M-30.02M-25.89M74.05M-285.00K

Ufp Technologies Technical Analysis

Technical Analysis Sentiment
Positive
Last Price199.05
Price Trends
50DMA
213.38
Positive
100DMA
211.28
Positive
200DMA
218.31
Positive
Market Momentum
MACD
1.07
Negative
RSI
56.58
Neutral
STOCH
85.65
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UFPT, the sentiment is Positive. The current price of 199.05 is below the 20-day moving average (MA) of 219.26, below the 50-day MA of 213.38, and below the 200-day MA of 218.31, indicating a bullish trend. The MACD of 1.07 indicates Negative momentum. The RSI at 56.58 is Neutral, neither overbought nor oversold. The STOCH value of 85.65 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UFPT.

Ufp Technologies Risk Analysis

Ufp Technologies disclosed 28 risk factors in its most recent earnings report. Ufp Technologies reported the most risks in the "Macro & Political" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Ufp Technologies Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$1.73B26.0618.31%29.47%23.24%
74
Outperform
$1.42B18.774.77%-0.23%
67
Neutral
$1.23B19.336.60%1.98%4.69%-51.57%
58
Neutral
$2.24B-194.83-2.45%9.81%-1067.00%
58
Neutral
$830.51M-39.62-12.91%23.27%43.90%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
45
Neutral
$1.02B-2.02-38.71%4.99%-7151.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
UFPT
Ufp Technologies
224.86
-27.99
-11.07%
CNMD
Conmed
39.95
-27.94
-41.15%
AORT
Artivion
46.55
18.07
63.45%
IART
Integra Lifesciences
13.05
-8.75
-40.14%
AHCO
AdaptHealth
9.97
-0.31
-3.02%
SIBN
SI-Bone
20.25
7.00
52.83%

Ufp Technologies Corporate Events

Business Operations and Strategy
UFP Technologies Highlights Strategic Focus in Investor Update
Positive
Dec 2, 2025

UFP Technologies has released updated presentation materials for investor meetings, highlighting its strategic focus on high-margin, long-term manufacturing opportunities in the medical device market. The company emphasizes its expertise in design, materials, and global manufacturing, aiming to strengthen customer relationships and expand its presence in various markets, including medical, aerospace, and defense. The announcement underscores UFP Technologies’ commitment to innovation and growth, with potential implications for stakeholders in terms of increased production capacity and market expansion.

Executive/Board ChangesBusiness Operations and Strategy
UFP Technologies Announces CEO Retirement and Succession
Neutral
Dec 2, 2025

On December 1, 2025, UFP Technologies announced the retirement of its long-serving CEO, R. Jeffrey Bailly, effective June 4, 2026. Bailly, who has led the company for 31 years, will transition to the role of Executive Chairman of the Board. Mitchell Rock, currently the President of UFP Technologies, will succeed Bailly as CEO. Rock has been with the company since 1991 and has held various leadership roles, demonstrating a deep understanding of the markets UFP serves. This leadership transition is expected to continue the company’s strategic growth and maintain its strong market position.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 09, 2025